Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

70 results

  1. ... Meek CL, Gadsby R, et al. Efficacy and safety of DPP-IV inhibitors for the treatment of older people with Type ... CL, Gadsby R, et al. The tolerability and safety of DPP-4 inhibitors for the treatment of older people with type ...
  2. ... PubMed : 28349174 ] [ CrossRef ] 21. Compare the efficacy and safety of dipeptidyl peptidase-4 inhibitors with other oral hypoglycemic agents in type 2 ... 1166. IshiharaH, YamaguchiS, NakaoI, et al. Efficacy and safety of ipragliflozin, an SGLT2 inhibitor, add-on to insulin in Japanese patients: results ...
  3. ... A, Brösse I, Wiemer-Kruel A, et al. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under ...
  4. ... Kim C, Lee DY, Park J, et al. Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid ...
  5. ... Excretion Absorption Inhibition of Enzymes Phosphatases A-1 Inhibitor of hyaluronidase Enolase Cereal phytase Amylase - Chemical conjunctivitis (Acute) Clinical (humans) Experimental animals - mice, ...
  6. ... a BRAF inhibitor with or without a MEK inhibitor. Evidence (lifileucel): A multicenter, multicohort, open-label trial ( C-144-01 [ NCT02360579 ]) evaluated the efficacy and safety of lifileucel in patients with unresectable or metastatic ...
  7. ... our review. For comparison 1, the effectiveness and safety of adding an acid supressing agents (an H2 receptor antagonists or a protein pump inhibitor) to PERT therapy, 4 RCTs ( Durie 1980 , Heijerman ...
  8. ... ampullary cancer amputation amrubicin ... inhibitor anaplastic lymphoma kinase positive anaplastic thyroid cancer anastomosis ...
  9. ... investigations. After locating nulls for the Kunitz trypsin inhibitor and seed lectin, I elucidated the inheritance of soybean seed lacking or having greatly reduced amounts of lipoxygenase-1, B-amylase and urease. Breaking through the mental black impasse ...
  10. NLM Digital Collections - Review of intramural research (1965) 
    Publication: [Bethesda, Md.] : U.S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health
    ... that are deficient in the production of extracellular amylase and protease. One double mutant, producing neither of these enzymes, produces normal amounts of the ribonuclease. A report from another laboratory that a pow- erful inhibitor of the enzyme may be obtained from the ...
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · next · last